Short Interest in Clearmind Medicine Inc. (NASDAQ:CMND) Expands By 128.7%

by · The Cerbat Gem

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 100,877 shares, an increase of 128.7% from the December 31st total of 44,113 shares. Currently, 6.7% of the shares of the stock are sold short. Based on an average trading volume of 193,471 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 193,471 shares, the short-interest ratio is currently 0.5 days. Currently, 6.7% of the shares of the stock are sold short.

Clearmind Medicine Price Performance

Shares of Clearmind Medicine stock traded down $0.02 during trading hours on Friday, hitting $2.17. The company’s stock had a trading volume of 30,782 shares, compared to its average volume of 123,597. The stock has a 50 day moving average of $3.28 and a 200 day moving average of $25.24. Clearmind Medicine has a 12 month low of $1.74 and a 12 month high of $60.00. The company has a market capitalization of $3.26 million, a PE ratio of -0.07 and a beta of 1.36.

Institutional Investors Weigh In On Clearmind Medicine

A hedge fund recently raised its stake in Clearmind Medicine stock. AdvisorShares Investments LLC raised its stake in Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) by 9.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 224,378 shares of the company’s stock after acquiring an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned about 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 96.05% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Clearmind Medicine to a “sell” rating in a research report on Saturday, December 20th.

View Our Latest Analysis on CMND

About Clearmind Medicine

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.

Featured Stories